ACS CAN: Executive order on pre-existing condition protections unlikely to help cancer patients and survivors

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

As part of a broader health care package, the Trump administration Sept. 24 issued an executive order to preserve health coverage protections for people with pre-existing conditions should the Supreme Court invalidate the Affordable Care Act.

A statement from Lisa Lacasse, president of the American Cancer Society Cancer Action Network follows:

“The executive order on pre-existing conditions falls far short of the protections already in place under the Affordable Care Act. The ACA’s rules against insurance denials or sky-high premiums based on someone’s health history have, for the last decade, been an essential lifeline to millions of American cancer patients and survivors.

“These patients cannot go back to a world wherein their ability to access lifesaving treatment is tied to an insurance market that is again allowed to restrict, rescind or reject their care. Should the administration succeed in its case to throw out the law, the executive order will offer no guaranteed patient protections in its place.”

Table of Contents

YOU MAY BE INTERESTED IN

In recent months, several directors of cancer centers, appearing on The Directors, a segment of The Cancer Letter Podcast, mentioned that their institutions are increasingly providing small grants—typically in the range of $50,000—to scientists to enable them to keep their labs open.
The long-awaited results from the RASolute 302 trial—a phase III clinical trial evaluating daraxonrasib, a RAS inhibitor, for the treatment of patients with previously treated, metastatic pancreatic ductal adenocarcinoma—have been read out. 
At a lecture at Yale Cancer Center recently, Robert A. Winn brandished a copy of a 32-year old booklet titled “Cancer at a Crossroads: A Report to Congress for the Nation,” using it as a show-and-tell prop in arguing that America’s cancer program is once again at a crossroads and therefore in urgent need of strategic thinking (The Cancer Letter, April 10, 2026).

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login